← All trials
NCT06284122
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 7, 2024
- Primary completion
- Nov 30, 2028
- Completion date
- Apr 30, 2034
- First posted
- Feb 28, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 790
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The Lymphoma Academic Research OrganisationLead sponsor
- Swiss Group for Clinical Cancer ResearchCollaborator
- Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaCollaborator
- The Lymphoma Study AssociationOfficial
- The Lymphoma Study AssociationCollaborator
- Swiss Cancer InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.